Home > Signaling Pathways>Metabolism>Thrombopoietin Receptor>Avatrombopag
Avatrombopag

This product is for research use only, not for human use. We do not sell to patients.

Avatrombopag
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
250mg$400Check With Us
500mg$700Check With Us
1g$1050Check With Us
email: [email protected]        [email protected]

Cat #: V3891 CAS #: 570406-98-3 Purity ≥ 98%

Description: Avatrombopag (formerly AKR-501, YM-477, AS-1670542; E-5501; trade name: Doptelet) is an orally-active small molecule thrombopoietin (TPO) receptor agonist that was used for the first time in 2008 to treat patients with chronic idiopathic thrombocytopenic purpura.

References: Fukushima-Shintani M, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82(4):247-254.

Top Publications Citing Invivochem Products
Product Catalog 2022
Bulletin Board
Guide to Product Handling
Publications Citing InvivoChem Products
Product Promise
Promise
Molecular Weight (MW)649.65
Molecular FormulaC29H34Cl2N6O3S2
CAS No.570406-98-3
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: ≥ 30 mg/mLr
Water: < 1 mg/mLr
Ethanol: < 1 mg/mL
SMILES CodeO=C(C1CCN(C2=NC=C(C(NC3=NC(C4=CC(Cl)=CS4)=C(N5CCN(C6CCCCC6)CC5)S3)=O)C=C2Cl)CC1)O
SynonymsYM477; AKR-501; E5501; AS 1670542; YM-477; AKR 501; E 5501; YM 477; AKR501; E-5501; AS1670542; AS-1670542
ProtocolIn VitroAvatrombopag promotes megakaryocyte colony formation from human CB CD34+ cells in a concentration-dependent fashion. The EC50 is 25 nM for Avatrombopag and the maximum activity of Avatrombopag is similar to that of rhTPO. Avatrombopag (0-100 nM) supports the proliferation of TPO receptor expressing Ba/F3 cell in a concentration-dependent fashion. Avatrombopag (0-3 μM) induces tyrosine phosphorylation of STAT3 and STAT5, and threonine phosphorylation of ERK in the cells, as did rhTPO. Avatrombopag (E5501; AKR-501) specifically targets the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as recombinant human TPO (rhTPO) did.
In VivoAvatrombopag (0.3-3 mg/kg; p.o.; daily for 14 days) increases the number of human platelets in NOD/SCID mice transplanted with human FL CD34+ cells.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM1.5393 mL7.6965 mL15.3929 mL30.7858 mL
5mM0.3079 mL1.5393 mL3.0786 mL6.1572 mL
10mM0.1539 mL0.7696 mL1.5393 mL3.0786 mL
20mM0.0770 mL0.3848 mL0.7696 mL1.5393 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
 
=
Concentration
 
×
Volume
 
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
 
×
 
Volume(start)
V1
 
=
 
Concentration(final)
C2
 
×
 
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O
Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.